Cargando…

Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade

Previous data indicate that Tankyrase inhibitors exert anti-growth functions in many cancer cell lines due to their ability to inactivate the YAP protooncogene. In the present manuscript, we investigated the effect of Tankyrase inhibitors on the growth of hepatocellular carcinoma (HCC) cell lines an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Jiaoyuan, Qiao, Yu, Pilo, Maria G., Cigliano, Antonio, Liu, Xianqiong, Shao, Zixuan, Calvisi, Diego F., Chen, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587291/ https://www.ncbi.nlm.nih.gov/pubmed/28877210 http://dx.doi.org/10.1371/journal.pone.0184068

Ejemplares similares

Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis
por: Wang, Haichuan, et al.
Publicado: (2020)

Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
por: Che, Li, et al.
Publicado: (2019)

Loss of Pten synergizes with c-Met to promote hepatocellular carcinoma development via mTORC2 pathway
por: Xu, Zhong, et al.
Publicado: (2018)

Corrigendum: Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma
por: Che, Li, et al.
Publicado: (2022)

Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells
por: Ma, Li, et al.
Publicado: (2015)

Focal adhesion kinase activation limits efficacy of Dasatinib in c‐Myc driven hepatocellular carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2018)

Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations
por: Troilo, Albino, et al.
Publicado: (2016)

The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance
por: Quackenbush, Kevin S., et al.
Publicado: (2016)

Tankyrase 1 and Tankyrase 2 Are Essential but Redundant for Mouse Embryonic Development
por: Chiang, Y. Jeffrey, et al.
Publicado: (2008)

Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta
por: Martino-Echarri, Estefania, et al.
Publicado: (2016)

2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors
por: Nkizinkiko, Yves, et al.
Publicado: (2018)

Tankyrase Inhibitor for Cardiac Tissue Regeneration: an In-silico Approach
por: Hosseini, Faezeh Sadat, et al.
Publicado: (2021)

The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
por: Cigliano, Antonio, et al.
Publicado: (2022)

Novel Binding Mode of a Potent and Selective Tankyrase Inhibitor
por: Gunaydin, Hakan, et al.
Publicado: (2012)

Formation of Tankyrase Inhibitor-Induced Degradasomes Requires Proteasome Activity
por: Pedersen, Nina Marie, et al.
Publicado: (2016)

Discovery of a Novel Triazolopyridine Derivative as a Tankyrase Inhibitor
por: Ryu, Hwani, et al.
Publicado: (2021)

FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases
por: Gustafson, Carl T., et al.
Publicado: (2017)

Correction: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
por: Cigliano, Antonio, et al.
Publicado: (2023)

Pivotal Role of Fatty Acid Synthase in c-MYC Driven Hepatocarcinogenesis
por: Jia, Jiaoyuan, et al.
Publicado: (2020)

Novel insight into the function of tankyrase
por: Kim, Mi Kyung
Publicado: (2018)

Activation mechanisms of the Hippo kinase signaling cascade
por: Bae, Sung Jun, et al.
Publicado: (2018)

Whole proteome analysis of human tankyrase knockout cells reveals targets of tankyrase-mediated degradation
por: Bhardwaj, Amit, et al.
Publicado: (2017)

The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models
por: Ribback, Silvia, et al.
Publicado: (2016)

Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2
por: Qiu, Wei, et al.
Publicado: (2014)

Identification of response signatures for tankyrase inhibitor treatment in tumor cell lines
por: Mygland, Line, et al.
Publicado: (2021)

Oncogenic potential of N-terminal deletion and S45Y mutant β-catenin in promoting hepatocellular carcinoma development in mice
por: Qiao, Yu, et al.
Publicado: (2018)

Tankyrase regulates epithelial lumen formation via suppression of Rab11 GEFs
por: Chandrakumar, Arun A., et al.
Publicado: (2021)

Tankyrases as modulators of pro-tumoral functions: molecular insights and therapeutic opportunities
por: Zamudio-Martinez, Esteban, et al.
Publicado: (2021)

Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice
por: Cigliano, Antonio, et al.
Publicado: (2017)

Structural basis of tankyrase activation by polymerization
por: Pillay, Nisha, et al.
Publicado: (2022)

WIKI4, a Novel Inhibitor of Tankyrase and Wnt/ß-Catenin Signaling
por: James, Richard G., et al.
Publicado: (2012)

3D imaging of colorectal cancer organoids identifies responses to Tankyrase inhibitors
por: Badder, Luned M., et al.
Publicado: (2020)

Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
por: Ryan, Kevin, et al.
Publicado: (2021)

Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma
por: Liu, Xianqiong, et al.
Publicado: (2019)

Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice
por: Hu, Junjie, et al.
Publicado: (2016)

PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men
por: Ribback, Silvia, et al.
Publicado: (2015)

Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines
por: Wang, Wenhui, et al.
Publicado: (2021)

The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006)

Evidence for tankyrases as antineoplastic targets in lung cancer
por: Busch, Alexander M, et al.
Publicado: (2013)

Tankyrases: Structure, Function and Therapeutic Implications in Cancer
por: Haikarainen, Teemu, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ju5h0cihqn9s9ves2hktg8mmo8